Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marina Y. Konopleva"'
Autor:
Tapan M. Kadia, Patrick K. Reville, Xuemei Wang, Caitlin R. Rausch, Gautam Borthakur, Naveen Pemmaraju, Naval G. Daver, Courtney D. DiNardo, Koji Sasaki, Ghayas C. Issa, Maro Ohanian, Guillermo Montalban-Bravo, Nicholas J. Short, Nitin Jain, Alessandra Ferrajoli, Kapil N. Bhalla, Elias Jabbour, Koichi Takahashi, Rashmi Malla, Kelly Quagliato, Rashmi Kanagal-Shamanna, Uday R. Popat, Michael Andreeff, Guillermo Garcia-Manero, Marina Y. Konopleva, Farhad Ravandi, Hagop M. Kantarjian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(33)
PURPOSE The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone. We hypothesized that the addition of venetoclax to cladribi
Autor:
Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan, Naval G. Daver, Courtney D. DiNardo, Elias J. Jabbour, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Y. Konopleva, Michael Andreeff, Farhad Ravandi‐Kashani, Koji Sasaki, Ghayas C. Issa
Publikováno v:
Cancer. 129:1856-1865
Autor:
Zhihong Zeng, Abhishek Maiti, Shelley Herbrich, Tianyu Cai, Antonio Cavazos, Taylor Manzella, Helen Ma, Kala Hayes, Jairo Matthews, Courtney D. DiNardo, Naval G. Daver, Marina Y. Konopleva
Publikováno v:
Cancer. 129:531-540
A recent breakthrough therapy combining the BCL-2 inhibitor venetoclax with hypomethylating agents (HMAs) targeting DNA methyltransferase has improved outcomes for patients with acute myeloid leukemia (AML), but the responses and long-term survival i
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:652-658
Autor:
Ajay Sheshadri, Alberto A. Goizueta, Vickie R. Shannon, David London, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Farhad Ravandi‐Kashani, Tapan M. Kadia, Marina Y. Konopleva, Courtney D. DiNardo, Sherry Pierce, Abdulrazzak Zarifa, Aya A. Albittar, Linda L. Zhong, Fechukwu O. Akhmedzhanov, Muhammad H. Arain, Mansour Alfayez, Ahmad Alotaibi, Mehmet Altan, Aung Naing, Tito R. Mendoza, Myrna C. B. Godoy, Girish Shroff, Sang T. Kim, Saadia A. Faiz, Dimitrios P. Kontoyiannis, Fareed Khawaja, Kristofer Jennings, Naval G. Daver
Publikováno v:
Cancer. 128:2736-2745
Immune checkpoint inhibitors (ICI), combined with hypomethylating agents, can be used to treat acute myeloid leukemia (AML), but this strategy results in a high rate of pneumonitis. The authors sought to determine risk factors for pneumonitis develop
Autor:
Alexandre Bazinet, Faezeh Darbaniyan, Tapan M. Kadia, Sangeetha Venugopal, Rashmi Kanagal‐Shamanna, Courtney D. DiNardo, Gautam Borthakur, Elias J. Jabbour, Naval G. Daver, Naveen Pemmaraju, Marina Y. Konopleva, Farhad Ravandi, Koji Sasaki, Kelly S. Chien, Danielle Hammond, Sherry A. Pierce, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo
Publikováno v:
CancerREFERENCES.
Patients with higher risk chronic myelomonocytic leukemia (CMML) have limited therapeutic options beyond hydroxyurea and hypomethylating agents (HMAs). Regimens based on a backbone of cladribine (CLAD), low-dose cytarabine (LDAC), and an HMA are effe
Autor:
Lina Han, Antonio Cavazos, Natalia Baran, Qi Zhang, Vinitha Mary Kuruvilla, Jason P Gay, Ningping Feng, Venkata Lokesh Battula, Hagop M. Kantarjian, Naval G. Daver, Joseph R Marszalek, Michael Andreeff, Marina Y Konopleva
Publikováno v:
Blood. 134:5161-5161
Acute myeloid leukemia (AML) is initiated and maintained by a relatively rare leukemia stem cells (LSCs) capable of self-renewal and proliferation. Recent data showed that LSCs (Lagadinou et al. Cell Stem Cell 2013) and residual cytarabine (Ara-C)-re
Autor:
Courtney D. DiNardo, Marina Y Konopleva, Hagop M. Kantarjian, John S. Welch, Wei Qiao, Jing Ning, Sherry A. Pierce, Kenneth Vaughan, Robin Thomas, Susan Tse, Shadiat L Adewale, Allison Wade, Carol A. Bivins, Helen Ma, Antonio Cavazos, Qi Zhang, Julio A Guerrero, Rita Maduike, Maitrayee Goswami, Zhining Chen, Sergej Konoplev, Sa A Wang, Philip A. Thompson, Michael E. Rytting, Lucia Masarova, Elias Jabbour, Ghayas C. Issa, Alessandra Ferrajoli, Prithviraj Bose, Michael Andreeff, Koji Sasaki, Guillermo Montalban Bravo, Steven M. Kornblau, Nitin Jain, Musa E. Yilmaz, Koichi Takahashi, Tapan M. Kadia, Christopher B. Benton, Yesid Alvarado, Nicholas J. Short, Maro Ohanian, Kiran Naqvi, Gautam M. Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Naval G. Daver, Naveen Pemmaraju, Jorge E. Cortes, Caitlin R. Rausch, Abhishek Maiti
Publikováno v:
Blood. 134:738-738
Background: Acute myeloid leukemia (AML) outcomes in the elderly, particularly intensive chemotherapy (IC)-ineligible patients (pts), are poor. Venetoclax (VEN), a BCL2 inhibitor, in combination with low-intensity regimens has shown excellent efficac